Alnylam Pharma Receives a Hold from Leerink SwannBy Ryan Adsit
According to TipRanks.com, Matteis is a 4-star analyst with an average return of 6.8% and a 56.5% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Aquinox Pharmaceuticals, and Paratek Pharmaceuticals.
Currently, the analyst consensus on Alnylam Pharma is Moderate Buy and the average price target is $72.80, representing a 60.5% upside.
In a report issued on November 3, Barclays also reiterated a Hold rating on the stock with a $50 price target.
Based on Alnylam Pharma’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $13.65 million and GAAP net loss of $104 million. In comparison, last year the company earned revenue of $6.32 million and had a GAAP net loss of $76.79 million.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALNY in relation to earlier this year. Last month, John Maraganore, the CEO of ALNY bought 7,540 shares for a total of $99,994.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.